Wilson Sonsini Goodrich & Rosati advised Aytu BioPharma on the transaction. Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU) and Lupin Pharma Canada Ltd (“Lupin”), a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Vertos Medical Inc. on the transaction. Stryker (NYSE: SYK), a global leader in medical technologies, announced a definitive agreement to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ripple on the transaction. Ripple Therapeutics Corporation (Ripple) announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Novo Holdings on the transaction. Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, announced the close of a $103 million Series A...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised ABL on the deal. ABL Bio, Inc., a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised WuXi AppTec on the deal. WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in...
You must be a Standard 1 Year member to access this content.
